GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 05 2026
0mins
Should l Buy HELP?
Source: PRnewswire
- Market Growth Potential: The global market for Generalized Anxiety Disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a robust annual growth rate of approximately 9%, driven by increasing awareness of mental health and demand for innovative solutions.
- Diverse Treatment Options: In addition to traditional anti-anxiety and antidepressant medications, the rise of cognitive-behavioral therapy and digital mental health tools has enhanced accessibility and effectiveness, allowing patients to manage symptoms in more flexible ways.
- Helus Pharma Drug Development: Helus Pharma announced positive topline results from its Phase 2 signal detection study for HLP004, indicating significant potential for this treatment to benefit adults with moderate-to-severe GAD who have not responded to existing therapies, thus offering new hope for underserved patients.
- Investment Outlook: As mental health care becomes increasingly integrated into mainstream healthcare systems, the broader anxiety treatment market is expected to exceed $12 billion in the next decade, with ongoing investments from companies and investors likely to drive long-term growth in this sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HELP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HELP
Wall Street analysts forecast HELP stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.500
Low
22.00
Averages
41.17
High
55.00
Current: 5.500
Low
22.00
Averages
41.17
High
55.00
About HELP
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Helus Pharma Welcomes White House Executive Order on Psychedelic Treatments
- Policy Driving Innovation: The White House's new Executive Order aims to accelerate research and regulatory pathways for mental health treatments, reflecting the urgent need for new options, with Helus Pharma actively contributing to this progress through the development of its HLP003 program.
- Breakthrough Therapy Designation: Helus Pharma's HLP003 is currently in Phase 3 clinical development and has received Breakthrough Therapy designation from the FDA for adjunctive treatment of major depressive disorder, showcasing the company's strategic positioning to meet market demands.
- Funding Support and Coordination: The Executive Order includes increased federal funding to support state-level programs and strengthens coordination among the Department of Health and Human Services, FDA, and Department of Veterans Affairs, creating a favorable policy environment for Helus Pharma's innovative drug development.
- Significant Market Potential: Helus Pharma believes that with policy momentum and the accumulation of clinical evidence, more patients will benefit from novel mental health treatments, particularly where existing therapies are insufficient, positioning the company to fill this market gap.
See More
Helus Pharma CEO Michael Colais Steps Down Immediately
- Executive Change: Helus Pharma announced that CEO Michael Colais has stepped down immediately at the request of the board, indicating a significant leadership shift that may impact investor confidence.
- Interim Leadership: Co-founder and executive chairman Eric So has been appointed as interim CEO to ensure continuity of leadership, helping the company maintain stability during the transition while searching for a new CEO.
- Successor Search: The board has initiated a search process for a permanent CEO, a move that could influence the company's strategic direction and future development, prompting investors to monitor subsequent developments closely.
- Market Reaction: Helus Pharma's stock rose 8.73% in pre-market trading to $5.98, reflecting market optimism regarding the new leadership and potential confidence in the company's future prospects.
See More
Helus Pharma Announces Transition in Leadership; Eric So to Take on Interim CEO Role
Leadership Change: Helus Pharma has announced a transition in its Chief Executive Officer position.
Interim Appointment: Eric Soto will assume the role of interim Chief Executive Officer during this transition period.
See More
Trump Signs Executive Order to Accelerate Psychedelic Drug Reviews
- Market Reaction: Following President Trump's executive order, shares of psychedelic drug developers surged in premarket trading, with Atai Life Sciences up 21%, Definium Therapeutics rising 15%, and Compass Pathways climbing 26%, indicating strong market confidence in the psychedelic sector.
- Executive Order Details: The order directs the FDA to expedite reviews of psychedelic drugs, particularly ibogaine for treating PTSD, depression, and addiction, potentially reducing review times from 6-10 months to just 1-2 months, significantly enhancing the industry's outlook.
- Government Funding Support: Trump announced a $50 million allocation for federal research into ibogaine, providing crucial financial backing for the development of psychedelic drugs and further propelling industry growth.
- Regulatory Risk Mitigation: Analysts noted that the executive order represents a government endorsement of psychedelics, reducing regulatory risks and potentially facilitating legislative efforts to expand access to psychedelic therapies, reflecting bipartisan interest and support in this field.
See More
Trump Administration to Examine Safety of Psychedelic Drug for PTSD
- Psychedelic Research Advancement: The Trump administration is drafting an executive order indicating a willingness to further investigate the safety and efficacy of ibogaine, a psychedelic used for treating PTSD, which is expected to accelerate clinical research in this area.
- Positive Market Reaction: Following the announcement, stocks of companies like Clearmind Medicine (CMND), Atai Beckley (ATAI), and Cybin (HELP) rose, reflecting market optimism regarding the potential applications of psychedelics in mental health treatment.
- Strait of Hormuz Passage Statement: Iran's Foreign Minister declared that commercial vessels can fully pass through the Strait of Hormuz during the ceasefire in Lebanon, while Trump confirmed normal passage but maintained a naval blockade against Iran, highlighting the complexities of geopolitical tensions in the region.
- AI Model Utilization: The U.S. government is preparing to make Anthropic PBC's AI model Mythos available to major federal agencies despite cybersecurity risks, indicating a balancing act between promoting technological innovation and ensuring data security.
See More
Helus Pharma Appoints New SVP of Medical Affairs
- Leadership Enhancement: Helus Pharma has appointed Dr. Ken Kramer as Senior Vice President of Medical Affairs, leveraging his 25 years of neuroscience experience to enhance the company's scientific and clinical engagement, thereby advancing drug development efforts.
- Rich Industry Background: Dr. Kramer previously served as Vice President at Bristol Myers Squibb, where he successfully launched the first new schizophrenia treatment in over 70 years, showcasing his deep capabilities in medical strategy and product launches, which are expected to positively impact Helus's product pipeline.
- Commitment to Innovation: Dr. Kramer emphasized Helus's commitment to innovation in treating neuropsychiatric disorders, particularly through the development of novel serotonergic agonists aimed at addressing unmet needs in depression and anxiety, which is anticipated to improve patient outcomes significantly.
- Global Market Expansion: Operating in the U.S., Canada, the U.K., and Ireland, Helus Pharma's strategic growth will be further propelled by Dr. Kramer's leadership, enhancing the company's competitive position in the neuroscience sector globally.
See More
Helus Pharma Welcomes White House Executive Order on Psychedelic Treatments
- Policy Driving Innovation: The White House's new Executive Order aims to accelerate research and regulatory pathways for mental health treatments, reflecting the urgent need for new options, with Helus Pharma actively contributing to this progress through the development of its HLP003 program.
- Breakthrough Therapy Designation: Helus Pharma's HLP003 is currently in Phase 3 clinical development and has received Breakthrough Therapy designation from the FDA for adjunctive treatment of major depressive disorder, showcasing the company's strategic positioning to meet market demands.
- Funding Support and Coordination: The Executive Order includes increased federal funding to support state-level programs and strengthens coordination among the Department of Health and Human Services, FDA, and Department of Veterans Affairs, creating a favorable policy environment for Helus Pharma's innovative drug development.
- Significant Market Potential: Helus Pharma believes that with policy momentum and the accumulation of clinical evidence, more patients will benefit from novel mental health treatments, particularly where existing therapies are insufficient, positioning the company to fill this market gap.
See More
Helus Pharma CEO Michael Colais Steps Down Immediately
- Executive Change: Helus Pharma announced that CEO Michael Colais has stepped down immediately at the request of the board, indicating a significant leadership shift that may impact investor confidence.
- Interim Leadership: Co-founder and executive chairman Eric So has been appointed as interim CEO to ensure continuity of leadership, helping the company maintain stability during the transition while searching for a new CEO.
- Successor Search: The board has initiated a search process for a permanent CEO, a move that could influence the company's strategic direction and future development, prompting investors to monitor subsequent developments closely.
- Market Reaction: Helus Pharma's stock rose 8.73% in pre-market trading to $5.98, reflecting market optimism regarding the new leadership and potential confidence in the company's future prospects.
See More
Helus Pharma Announces Transition in Leadership; Eric So to Take on Interim CEO Role
Leadership Change: Helus Pharma has announced a transition in its Chief Executive Officer position.
Interim Appointment: Eric Soto will assume the role of interim Chief Executive Officer during this transition period.
See More
Trump Signs Executive Order to Accelerate Psychedelic Drug Reviews
- Market Reaction: Following President Trump's executive order, shares of psychedelic drug developers surged in premarket trading, with Atai Life Sciences up 21%, Definium Therapeutics rising 15%, and Compass Pathways climbing 26%, indicating strong market confidence in the psychedelic sector.
- Executive Order Details: The order directs the FDA to expedite reviews of psychedelic drugs, particularly ibogaine for treating PTSD, depression, and addiction, potentially reducing review times from 6-10 months to just 1-2 months, significantly enhancing the industry's outlook.
- Government Funding Support: Trump announced a $50 million allocation for federal research into ibogaine, providing crucial financial backing for the development of psychedelic drugs and further propelling industry growth.
- Regulatory Risk Mitigation: Analysts noted that the executive order represents a government endorsement of psychedelics, reducing regulatory risks and potentially facilitating legislative efforts to expand access to psychedelic therapies, reflecting bipartisan interest and support in this field.
See More
Trump Administration to Examine Safety of Psychedelic Drug for PTSD
- Psychedelic Research Advancement: The Trump administration is drafting an executive order indicating a willingness to further investigate the safety and efficacy of ibogaine, a psychedelic used for treating PTSD, which is expected to accelerate clinical research in this area.
- Positive Market Reaction: Following the announcement, stocks of companies like Clearmind Medicine (CMND), Atai Beckley (ATAI), and Cybin (HELP) rose, reflecting market optimism regarding the potential applications of psychedelics in mental health treatment.
- Strait of Hormuz Passage Statement: Iran's Foreign Minister declared that commercial vessels can fully pass through the Strait of Hormuz during the ceasefire in Lebanon, while Trump confirmed normal passage but maintained a naval blockade against Iran, highlighting the complexities of geopolitical tensions in the region.
- AI Model Utilization: The U.S. government is preparing to make Anthropic PBC's AI model Mythos available to major federal agencies despite cybersecurity risks, indicating a balancing act between promoting technological innovation and ensuring data security.
See More
Helus Pharma Appoints New SVP of Medical Affairs
- Leadership Enhancement: Helus Pharma has appointed Dr. Ken Kramer as Senior Vice President of Medical Affairs, leveraging his 25 years of neuroscience experience to enhance the company's scientific and clinical engagement, thereby advancing drug development efforts.
- Rich Industry Background: Dr. Kramer previously served as Vice President at Bristol Myers Squibb, where he successfully launched the first new schizophrenia treatment in over 70 years, showcasing his deep capabilities in medical strategy and product launches, which are expected to positively impact Helus's product pipeline.
- Commitment to Innovation: Dr. Kramer emphasized Helus's commitment to innovation in treating neuropsychiatric disorders, particularly through the development of novel serotonergic agonists aimed at addressing unmet needs in depression and anxiety, which is anticipated to improve patient outcomes significantly.
- Global Market Expansion: Operating in the U.S., Canada, the U.K., and Ireland, Helus Pharma's strategic growth will be further propelled by Dr. Kramer's leadership, enhancing the company's competitive position in the neuroscience sector globally.
See More
